I was just basing it on the $40m profit (based on a 10% profit share) for MNTA that seems to be the consensus in the 2-way plus authorized generic case…
In the multiple-generic case, MNTA’s take is roughly 10% of sales, not 10% of profits.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”